These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21128694)

  • 1. The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.
    Delea TE; Thomas SK; Hagiwara M
    CNS Drugs; 2011 Jan; 25(1):53-66. PubMed ID: 21128694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
    Delea TE; Thomas SK; Hagiwara M; Mancione L
    Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
    Groenendaal H; Tarrants ML; Armand C
    Clin Drug Investig; 2010; 30(11):789-98. PubMed ID: 20818839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
    Lew MF; Somogyi M; McCague K; Welsh M;
    Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
    Eggert K; Skogar O; Amar K; Luotonen L; Kuoppamäki M; Leinonen M; Nissinen H; Oertel W
    J Neural Transm (Vienna); 2010 Mar; 117(3):333-42. PubMed ID: 20013007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
    Palmer CS; Nuijten MJ; Schmier JK; Subedi P; Snyder EH
    Pharmacoeconomics; 2002; 20(9):617-28. PubMed ID: 12141889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
    Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
    Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.
    Tolosa E; Hernández B; Linazasoro G; López-Lozano JJ; Mir P; Marey J; Kulisevsky J
    J Neural Transm (Vienna); 2014 Apr; 121(4):357-66. PubMed ID: 24253234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H; Emre M
    Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa dose maintenance or reduction in patients with Parkinson's disease transitioning to levodopa/carbidopa/entacapone.
    Park J; Kim Y; Youn J; Lee PH; Sohn YH; Koh SB; Lee JY; Baik JS; Cho JW
    Neurol India; 2017; 65(4):746-751. PubMed ID: 28681744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.
    Trenkwalder C; Kuoppamäki M; Vahteristo M; Müller T; Ellmén J
    Neurology; 2019 Mar; 92(13):e1487-e1496. PubMed ID: 30824559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacoeconomic aspects of combined treatment of advanced stage of Parkinson's disease].
    Rudakova AV; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6. Vyp. 2):96-100. PubMed ID: 28980620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.
    Kuoppamäki M; Sauramo A; Korpela K; Vahteristo M; Kailajärvi M; Lehtinen T; Ellmén J
    Int J Clin Pharmacol Ther; 2010 Nov; 48(11):756-60. PubMed ID: 20979935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.
    Liao X; Wu N; Liu D; Shuai B; Li S; Li K
    Neurol Sci; 2020 Aug; 41(8):2045-2054. PubMed ID: 32162166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.
    Ingman K; Naukkarinen T; Vahteristo M; Korpela I; Kuoppamäki M; Ellmén J
    Eur J Clin Pharmacol; 2012 Mar; 68(3):281-9. PubMed ID: 21927836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
    Martínez-Martín P; Hernández B; Ricart J;
    Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.